Results 21 to 30 of about 63,889 (276)

Infliximab‐induced seizures in a patient with Crohn’s disease: a case report

BMC Gastroenterology, 2021
Background Infliximab-induced seizures in patients with Crohn’s disease are extremely rare and the mechanism of infliximab-induced seizures is unclear.
Zhijie Lv, Xiaoqi Zhang, Li Wu
doaj   +1 more source

Development and validation of enzyme-linked immunosorbent assays for the measurement of infliximab and anti-drug antibody levels

Heliyon, 2023
Infliximab and its anti-drug antibody (ADA) serum concentrations exhibit a strong correlation with clinical response and loss of response. The use of therapeutic drug monitoring to measure the concentration of infliximab and ADA can facilitate clinical ...
Dong Xiang, Ninghong Li, Lu Liu, Hengyi Yu, Xiping Li, Tinghui Zhao, Dong Liu, Xuepeng Gong   +7 more
doaj   +1 more source

Safety aspects of infliximab in inflammatory bowel disease patients - A retrospective cohort study in 100 patients of a German University Hospital [PDF]

, 2004
Background: Infliximab, a chimeric anti-tumour necrosis factor monoclonal antibody with potent anti-inflammatory effects, represents an effective treatment option in patients with severe inflammatory bowel disease (IBD).
Seiderer, J., Burkhard Göke, Göke, B., Ochsenkühn, Thomas, Thomas Ochsenkühn, Julia Seiderer   +5 more
core   +1 more source

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

BMC Musculoskeletal Disorders, 2011
Background This study in patients with rheumatoid arthritis (RA) treated with infliximab describes prospectively the course of (anti)infliximab levels within an infusioncycle to assess at what moment patients develop low/no infliximab trough levels and ...
van Riel Piet LCM, Hekster Yechiel A, Wolbink GJ, den Broeder Alfons A, van den Bemt Bart JF, Benraad Bart, van den Hoogen Frank HJ   +6 more
doaj   +1 more source

Development of Anti-bodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis.

مجلة كلية الطب, 2015
Background: Rheumatoid arthritis is a common chronic and destructive autoimmune arthropathy .Treatment with infliximab gives great improvement to a large numbers of patients with RA ,however, in some patients after prolonged treatment infliximab can ...
Mohammed A. Al-Karkhi, Muhammed M. Al-Ani, Nizar A. Jassim   +2 more
doaj   +1 more source

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab.

PLoS ONE, 2015
ObjectiveIn patients with postoperative recurrence of Crohn's disease endoscopic and clinical remission can be maintained for up to 1 year with low infliximab doses (3 mg/Kg).
Dario Sorrentino, Marco Marino, Themistocles Dassopoulos, Dimitra Zarifi, Tiziana Del Bianco   +4 more
doaj   +1 more source

Serum trough levels of infliximab are not associated with peripheral arthralgia activity in patients with inflammatory bowel disease

BMJ Open Gastroenterology, 2021
Background Infliximab is an efficacious therapy for inflammatory bowel disease and may play a role in management of some extraintestinal manifestations.
Daniel J Stein, Andres J Yarur, Shaina Sekhri, Bharat Rao, Akanksha Mohananey, Poonam Beniwal-Patel, Alexandra Bruss   +6 more
doaj   +1 more source

Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of Ankylosing Spondylitis [PDF]

, 2013
Technology: Infliximab and comparator biological such as adalimumab, etanercept, golimumab. Conditions: Ankylosing spondylitis (AS) Issue: Infliximab is registered to be used in patients with AS.
Péntek, Márta
core   +1 more source

Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy.

PLoS Biology, 2019
During rheumatoid arthritis (RA) treatment, long-term injection of antitumor necrosis factor α antibodies (anti-TNFα Abs) may induce on-target toxicities, including severe infections (tuberculosis [TB] or septic arthritis) and malignancy.
Yun-Chi Lu, Chih-Hung Chuang, Kuo-Hsiang Chuang, I-Ju Chen, Bo-Cheng Huang, Wen-Han Lee, Hsin-Ell Wang, Jia-Je Li, Yi-An Cheng, Kai-Wen Cheng, Jaw-Yuan Wang, Yuan-Chin Hsieh, Wen-Wei Lin, Tian-Lu Cheng   +13 more
doaj   +1 more source

Specialized enteral nutrition therapy in Crohn’s disease patients on maintenance infliximab therapy: a meta-analysis

Therapeutic Advances in Gastroenterology, 2015
Objectives: Many patients with Crohn’s disease on infliximab maintenance therapy have recurrent symptoms despite an initial clinical response. Therefore, concomitant therapies have been studied.
Douglas L. Nguyen, Lena B. Palmer, Emily T. Nguyen, Stephen A. McClave, Robert G. Martindale, Matthew L. Bechtold   +5 more
doaj   +1 more source